疏肝理脾止泻汤治疗腹泻型肠易激综合征68例

目的:观察疏肝理脾止泻汤治疗腹泻型肠易激综合征(IBS-D)的临床疗效.方法:将136例随机按数字法分为治疗组和对照组各68例.治疗组采用疏肝理脾止泻汤治疗,1剂/d,口服和灌肠给药;对照组采用马来酸曲美布汀胶囊,100 mg/次,3次/d,口服,两组疗程为8周.采用IBS症状尺度表评分严重程度(IBS-BSS)、记录消化系主要症状评分、评价患者生活质量、记录汉密尔顿焦虑量表(HAMA)和汉密尔顿抑郁量表(HAMD)评分及记录随访期3个内复发例数.结果:治疗组疗效总有效率为89.71％优于对照组的72.05％ (P＜0.05);中医证候疗效总有效率为92.64％优于对照组的70.58％(P＜0.01);治疗组IBS-BSS,HAMA,HAMD评分低于对照组(P＜0.01),IBS-QOL评分明显升高且高于对照组(P＜0.01);治疗组腹痛、腹胀、排便次数、粪便形状及黏液便评分低于对照组(P＜ 0.01);对照组随访3个月累计复发率达88.23％,高于治疗组的58.82％ (P ＜0.01).结论:疏肝理脾止泻汤能改善IBS-D临床症状及精神心理症状,提高患者生活质量,临床疗效显著,且复发率低,值得临床使用.

Shugan Liqi Zhixie Tang in Treatment of 68 Patients with Diarrhea-predominant Irritable Bowel Syndrome

Objective: To observe the Shugan Liqi Zhixie Tang (SLZT) in treatment of 68 patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Method: One hundred and thirty-six cases with IBS-D were randomly divided into treatment group and control group, and each group had 68 cases. The treatment group was given SLZT, one dose/d, and they were used by oral and enema administration; the control group was given trimebutine maleate capsules, 100 mg/time, 3 times/d, and they were used by oral for 8 weeks. The symptoms severity were used by IBS scale table (IBS-BSS), and recorded the main digestive symptom score to evaluate the quality of life of patients, recorded Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) score and recorded the 3 months recurrent rate of follow-up period. Result: The total effective rate of the treatment group was 89.71% higher than 72.05% of the control group (P<0.05); total effective rate of the treaditional Chinese medicine syndromes in treatment group was 92.64% better than 70.58% of the control group (P<0.01); the IBS-BSS, HAMA, HAMD score of the treatment group were better than the control group (P<0.01), and IBS-QOL score was significantly higher and the control group (P<0.01); abdominal pain, bloating, stool frequency, stool shape and mucus score of the treatment group were better than the control group (P<0.01); the patients were followed up for 3 months, and the cumulative recurrence rate of the control group was 88.23% higher than 58.82% of the treatment group (P<0.01). Conclusion: SLZT in treatment of IBS-D can improve the clinical symptoms and psychological symptoms and improve the quality of life of patients, the clinical effect is significant, and the recurrence rate is low, which is worth to be applied in clinical.